BioRestorative Therapies, Inc. Stock News

MELVILLE, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc . (“BioRestorative” or the “Company”) (NASDAQ: BRTX ), a clinical stage company focused on stem cell-based ther

MELVILLE, NY / ACCESSWIRE / February 14, 2024 / BioRestorative Therapies (NASDAQ:BRTX) is a clinical-stage biotech company that is developing cell-based therapies to treat chronic lumbar disc disease

MELVILEE, N.Y., Feb. 06, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative" or the “Company”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies,

— Preliminary data includes 26 and 52-week follow-up end points as part of ongoing Phase 2 trial — — Company to host webcasted conference call today at 8:30am EST — MELVILLE, N.Y., Feb. 05, 20

— Blinded data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in poster presentation — — Company to host webcasted conference call to review data on February 5, 2024 at 8:30

--Notice of allowance will be the fourth U.S. patent granted under Company's ThermoStem ® program targeting obesity and metabolic disorders, including type 2 diabetes-- MELVILLE, N.Y., Dec. 12, 2023

MELVILLE, NY., Oct. 09, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies

MELVILLE, NY / ACCESSWIRE / September 18, 2023 / BioRestorative Therapies Inc. (NASDAQ:BRTX) ("BioRestorative") is a clinical-stage biotech company that is developing cell-based therapies to treat chr

-- BioRestorative to Leverage its Core Competencies in Cell Biology and Manufacturing to S upply B iologics for C osmetic A pplications in Strategic Agreement

--Site activation allows for patients in the S tate of New York to participate in the BRTX-100 t rial —

On July 25, 2023, Lance Alstodt, President, CEO, COB, and 10% Owner of BioRestorative Therapies Inc ( BRTX , Financial), made a significant purchase of 4200 shares of the company's stock. This move is

  BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes No Dose Limiting Toxicity (DLT) was Observed in the Patients in the Safety Run-In Segment of Study DSMB Recommendation Allows for Open Enrollment MELVILLE, N.Y. -- June 27, 2023 -- InvestorsHub NewsWire -- BioRestorativ...

MELVILLE, NY., June 16, 2023 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (the “Company” or “BioRetorative”) (NASDAQ: BRTX), a clinical stage company focused on stem cell-based therapies

Penny stocks to watch with news. The post 5 Penny Stocks To Watch With Big News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Melville, New York--(Newsfile Corp. - January 17, 2023) - BioRestorative Therapies (NASDAQ: BRTX) ("BioRestorative", "BRTX" or the "Company"), a clinical stage company focused on stem cell-based thera